Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Transfusion-dependent Beta-Thalassemia: early-phase trial registry
A small indexed set (4 trials) with no open enrollment listed right now.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · none currently recruiting · #4,115 of 28,707 conditions by registered trial count
Transfusion-dependent Beta-Thalassemia: 4 US clinical trials tracked, none currently recruiting.
Transfusion-dependent Beta-Thalassemia is the subject of 4 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 1 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Editas Medicine, running 1 of these trials.
Enrollment posture brief
Registry condition transfusion-dependent-beta-thalassemia
OPEN 0 | RECR 0% | LATE 1 | EARLY 2 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Transfusion-dependent Beta-Thalassemia has no open enrollment in this registry pull (4 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Transfusion-dependent Beta-Thalassemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Transfusion-dependent Beta-Thalassemia is recruiting below its size-band peers.
0 of 4 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
4 total, page 1 of 1
A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)
Agios Pharmaceuticals
NCT04770779
Long-term Follow-up of Subjects With Transfusion-Dependent β-Thalassemia (TDT) Treated With Ex Vivo Gene Therapy
Genetix Biotherapeutics
NCT02633943
EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in Participants With Transfusion-Dependent Beta Thalassemia (TDT)
Editas Medicine
NCT05444894
A Study to Assess the Safety, Tolerability, and Efficacy of ST-400 for Treatment of Transfusion-Dependent Beta-thalassemia (TDT)
Sangamo Therapeutics
NCT03432364
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Transfusion-dependent Beta-Thalassemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Transfusion-dependent Beta-Thalassemia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Transfusion-dependent Beta-Thalassemia page
4 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Transfusion-dependent Beta-Thalassemia trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Editas Medicine sponsors the most Transfusion-dependent Beta-Thalassemia trials on record, review their full trial history before evaluating a specific study. See Editas Medicine's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Transfusion-dependent Beta-Thalassemia condition card totals 4 registered trials; most-linked intervention ST-400 Investigational product; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.